• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原癌基因c-Mos产物通过丝裂原活化蛋白激酶(MAP激酶)依赖的机制刺激c-Jun转录活性。

The c-Mos proto-oncogene product stimulates c-Jun transcriptional activity by a MAP kinase-dependent mechanism.

作者信息

Sever R, Turner R

机构信息

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

出版信息

Biochem Biophys Res Commun. 1996 Nov 12;228(2):259-66. doi: 10.1006/bbrc.1996.1650.

DOI:10.1006/bbrc.1996.1650
PMID:8920903
Abstract

The AP-1 transcription factor family is subject to sophisticated regulation in response to cell growth and stress stimuli. We show here that the transcriptional activity of c-Jun, a key AP-1 component, is stimulated by overexpression of the c-Mos proto-oncogene product in mammalian cells. This stimulation requires serines 63 and 73 of c-Jun, indicating that it is likely to be mediated by proline-directed kinase(s). Co-transfection of MKP-1, a specific MAP kinase antagonist, blocks the stimulation of c-Jun by c-Mos, while co-transfection of a dominant negative form of c-Raf-1 does not. Conditioned medium from c-Mos transfected cells fails to activate c-Jun in recipient cells, arguing against the involvement of a diffusible mitogen. These data suggest that c-Mos exerts its effect on c-Jun directly through a MAP kinase, acting downstream of c-Raf-1.

摘要

AP-1转录因子家族在响应细胞生长和应激刺激时受到复杂的调控。我们在此表明,c-Jun(一种关键的AP-1成分)的转录活性在哺乳动物细胞中被c-Mos原癌基因产物的过表达所刺激。这种刺激需要c-Jun的丝氨酸63和73,表明它可能由脯氨酸定向激酶介导。特异性丝裂原活化蛋白激酶(MAP激酶)拮抗剂MKP-1的共转染可阻断c-Mos对c-Jun的刺激,而c-Raf-1的显性负性形式的共转染则不能。来自c-Mos转染细胞的条件培养基无法激活受体细胞中的c-Jun,这排除了可扩散有丝分裂原的参与。这些数据表明,c-Mos通过MAP激酶直接对c-Jun发挥作用,作用于c-Raf-1的下游。

相似文献

1
The c-Mos proto-oncogene product stimulates c-Jun transcriptional activity by a MAP kinase-dependent mechanism.原癌基因c-Mos产物通过丝裂原活化蛋白激酶(MAP激酶)依赖的机制刺激c-Jun转录活性。
Biochem Biophys Res Commun. 1996 Nov 12;228(2):259-66. doi: 10.1006/bbrc.1996.1650.
2
Signaling pathways in the induction of c-fos and c-jun proto-oncogenes by 3-methylcholanthrene.3-甲基胆蒽诱导c-fos和c-jun原癌基因过程中的信号通路。
Recept Signal Transduct. 1997;7(4):279-89.
3
c-Jun functions as a calcium-regulated transcriptional activator in the absence of JNK/SAPK1 activation.在没有JNK/SAPK1激活的情况下,c-Jun作为一种钙调节转录激活因子发挥作用。
EMBO J. 1999 Mar 1;18(5):1335-44. doi: 10.1093/emboj/18.5.1335.
4
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun.JNK磷酸化可解除HDAC3对c-Jun转录活性的依赖性抑制作用。
EMBO J. 2003 Jul 15;22(14):3686-95. doi: 10.1093/emboj/cdg364.
5
Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos.丝氨酸16及其磷酸化在c-Mos蛋白稳定化中起重要作用的证据。
Oncogene. 1999 Jul 29;18(30):4287-94. doi: 10.1038/sj.onc.1202804.
6
Phosphorylation of c-jun mediated by MAP kinases.由丝裂原活化蛋白激酶介导的c-jun磷酸化。
Nature. 1991 Oct 17;353(6345):670-4. doi: 10.1038/353670a0.
7
Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.mos原癌基因功能域的诱变分析以及对丝裂原活化蛋白激酶(MAPK)激活和DNA结合重要位点的鉴定。
Oncogene. 1995 Oct 19;11(8):1447-57.
8
Different promoter elements are required for the induced expression of c-fos and c-jun proto-oncogenes by the v-mos oncogene product.
New Biol. 1990 Feb;2(2):143-50.
9
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes.细胞外调节激酶1/2、Jun氨基末端激酶和c-Jun参与人单核细胞中核因子κB依赖性白细胞介素-6的表达。
J Immunol. 1999 Apr 15;162(8):4893-902.
10
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.显性负性Jun的表达可抑制升高的AP-1和NF-κB反式激活,并抑制人乳头瘤病毒永生化人角质形成细胞的锚定非依赖性生长。
Oncogene. 1998 May 28;16(21):2711-21. doi: 10.1038/sj.onc.1201798.